This page and related links last reviewed on August 20, 2013
(Ancillary to the Cancer Committee)
Reports to: Council on Scientific Affairs
Charge: To develop and maintain structured pathology reporting templates and related educational materials for cancer biomarker testing to aid in the diagnosis, treatment and prognosis of cancer patients.
Membership: The committee will consist of up to 16 members including the chair.
- Number of face-to-face meetings - 2
- Length of each meeting - 1 day
- Typical meeting days of the week - Saturday
- Location of meetings - Usually within 50 miles of an airport; one meeting in Chicago
- Number of conference calls - 24 per year; 1 to 1.5 hours each
- These calls represent the work of the committee proper and its individual panels.
- Hours of committee work required outside of meetings
- Committee Chair - 80 + hours per year
- Vice Chair and other members - 40-60 hours per year
Additional travel or time commitments: Attendance at CSA Leadership and Cancer Committee meetings for Chair, as needed.
- Develop the cancer biomarker reporting templates, mirroring the format and content guidelines of the CAP Cancer protocols as closely as possible.
- Act as “advisors” to the CAP regarding issues related to cancer biomarker reporting.
- Monitor new and emerging guidelines and expert consensus to create standardized biomarker reporting templates.
- Facilitate communication and collaboration between the end-user pathologists, the CAP Cancer Committee, other vested CAP Committees such as PERT, Molecular Oncology, Immunohistochemistry, and Cytopathology, as well as outside organization stakeholders.
- Collaborate with the PERT Committee and the CAP electronic Cancer Checklists (eCC) Team staff to help produce electronic versions of the CBRC templates, following the same management and workflow that is currently in place for converting the CAP Cancer Protocols to eCC format.
- Interest in promoting pathology as leaders in cancer biomarker reporting.
- Commitment to advancing excellence in cancer reporting and/or cancer biomarker standards.
- Opportunity to meet and work with pathologists and clinicians from a variety of practice settings and organizations
- Opportunity to publish materials
- Opportunity to speak at educational events
- Opportunity to participate in developing recommendations for the practice of pathology
Representation on committee beyond the CAP:
The Cancer Biomarker Reporting Committee has inbound liaisons from the following organizations:
- American College of Surgeons - National Cancer Data Base (ACoS-NCDB)
- American Joint Committee on Cancer (AJCC)
- American Society of Clinical Oncology (ASCO)
- Association for Molecular Pathology (AMP)
- Centers for Disease Control and Prevention - National Program of Cancer Registries (CDC-NPCR)
- Collaborative Stage Data Collection System (CS)
- HL7 Clinical Genomics Work Group (HL7-CGWG)
- National Cancer Institute - Surveillance Epidemiology and End Results (NCI-SEER)
- National Comprehensive Cancer Network (NCCN)
- North American Association of Central Cancer Registries (NAACCR)